Understanding the Prostate - Specific Antigen (PSA) Test for Prostate Conditions
Prostate cancer is one of the most common types of cancers in men. The Prostata PSA 5.8-treat gland, which exists only in men, is involved in the production of semen.
Cancer in the prostate often grows very slowly and remains within the gland. In some instances it can be more aggressive, which means it grows quickly and can spread beyond the prostate. Prostata PSA 5.8-treat factors will determine the best treatment plan, including the stage of the cancer, PSA level, grade of the tumor i. The prostate gland makes a protein called prostate-specific antigen, or PSA. A healthy man without prostate cancer should have a small amount of PSA circulating in his blood.
Some conditions related to the prostate can cause the gland to produce more PSA than normal. These include prostatitis, benign prostatic hyperplasia enlarged prostateand prostate cancer. A PSA test is a test that measures the levels of the protein Prostata PSA 5.8-treat the blood.
As a man ages, his PSA levels naturally rise. According to the National Cancer Institutemany organizations caution against routine PSA testing to screen for prostate cancer in men at average risk. However, PSA testing can be used to help diagnose prostate cancer, determine a prognosis for those who have prostate cancer, and track progression of the cancer or response to treatment.
Staging of prostate cancer is used to communicate how advanced the disease is and to help plan treatment. Stages range from 1 to 4, with the disease being most advanced in Prostata PSA 5.8-treat 4. There are a number of factors that go into this labeling. This staging system is based on the size or extent of the tumor, the number of lymph nodes involved, and whether or not the cancer has Prostata PSA 5.8-treat or metastasized to distant sites or organs.
Prognostic groups are further determined based on two additional factors: the PSA level and the Gleason score. PSA levels are just one factor used in determining the stage and prognostic groups of prostate cancer. Some men who have prostate cancer do not exhibit elevated PSA levels, and some noncancerous conditions, like a prostate infection or benign enlargement, can cause high PSA levels. Stage 1 prostate cancer is characterized by a Gleason score of less than 6: The cancer is restricted to one half of the prostate with no spreading to surrounding tissues and a Prostata PSA 5.8-treat level below The Gleason score Prostata PSA 5.8-treat cancer cells to normal cells.
The more the cells differ from normal cells, the higher the score and the more aggressive the cancer. Like the PSA level, it is just one piece of the puzzle.
By stage 2B, the tumor may have spread to the opposite side of the prostate gland, but it also may still be contained on one side. Prostata PSA 5.8-treat the tumor is still restricted to one half of the prostate, a Gleason score of 8 or higher or a PSA level of 20 or greater categorizes the cancer as stage 2B.
If the tumor has spread to both sides of the prostate then the stage is 2B regardless of the Gleason score and the PSA level. By the time prostate cancer has reached stage 3 or stage 4, the cancer is very advanced. At this point, the stage is determined by the extent of the spread Prostata PSA 5.8-treat the cancer, and the PSA level and Gleason score do not factor in the staging. In stage 3 the tumor has grown through the prostate capsule and may have invaded nearby tissue.
By stage 4 the tumor is fixed or immovable and invades nearby structures beyond the seminal vesicles. It may also have spread to distant sites like lymph nodes or bones. To determine the size and extent of the Prostata PSA 5.8-treat tumor, doctors use imaging techniques like CT Prostata PSA 5.8-treat, MRIs, PET scans, and biopsies of prostate and other tissue. Research has shown that using PSA to screen for cancer does not save lives.
On the other hand, it can cause harm by leading to more invasive procedures — like biopsies and surgery — that may not be necessary and can have complications and side effects. For this reason, the U. Preventive Services Task Force now recommends that men aged 55 to 69 decide for themselves whether to undergo a Prostata PSA 5.8-treat antigen PSA test, after talking it over with their doctor.
The task force recommends against screening for men over 70 because Prostata PSA 5.8-treat potential benefits do not outweigh the risks. It may be a useful tool for high-risk men, especially African-Americans or those with a family history of prostate cancer. If you are considering PSA screening you should understand the Prostata PSA 5.8-treat and benefits of this test. PSA testing does remain, however, an important tool in staging and monitoring prostate cancer once it has been diagnosed and helping assess response to treatment.
Learn more about prostate cancer symptoms, as Prostata PSA 5.8-treat as when it's time to take action. Prostate cancer commonly affects men. Learn about the stages of prostate cancer, what the PSA test detects, and the role it plays in staging. If you ejaculate frequently, your risk of getting prostate cancer may be reduced. But how often is frequent? And is this true for men of all ages? Adding these six foods to your diet may reduce your risk for prostate cancer.
Learn about treatments, symptoms, and outlook for stage 2 prostate cancer. Whether there's a link between prostate cancer and alcohol consumption has been widely speculated. Here's what you need to know.
How much do you know about prostate cancer? Test your knowledge. Prostate cancer affects Prostata PSA 5.8-treat prostate gland in men. Learn about risk factors, symptoms, treatments, and outlook. Free PSA may be used to help determine your risk for prostate cancer. Learn how this test differs from PSA test and biopsy. The PCA3 test may help determine your risk of prostate cancer.
Learn more about the procedure, cost, and more. Prostate-specific antigen PSA. Staging prostate cancer. Controversy over Prostata PSA 5.8-treat levels. What to Expect from Stage 2 Prostate Cancer. Read this next. Medically reviewed by Ricky Chen, MD. Medically reviewed by Seunggu Han, MD. Medically reviewed by Timothy J.
Medically reviewed by Judith Marcin, MD.